PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12489924-0 2002 Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines. pirarubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 12489924-0 2002 Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines. pirarubicin 110-121 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 12489924-1 2002 In this work, we sought to investigate the relation existing between MDR1 mRNA levels, the resistance factor (RF), and the efficiency of efflux of pirarubicin (THP) mediated by P-glycoprotein (P-gp) in multidrug-resistant (MDR) K562 sublines. pirarubicin 147-158 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 12489924-1 2002 In this work, we sought to investigate the relation existing between MDR1 mRNA levels, the resistance factor (RF), and the efficiency of efflux of pirarubicin (THP) mediated by P-glycoprotein (P-gp) in multidrug-resistant (MDR) K562 sublines. pirarubicin 147-158 ATP binding cassette subfamily B member 1 Homo sapiens 177-191 12489924-1 2002 In this work, we sought to investigate the relation existing between MDR1 mRNA levels, the resistance factor (RF), and the efficiency of efflux of pirarubicin (THP) mediated by P-glycoprotein (P-gp) in multidrug-resistant (MDR) K562 sublines. pirarubicin 147-158 ATP binding cassette subfamily B member 1 Homo sapiens 193-197 12489924-1 2002 In this work, we sought to investigate the relation existing between MDR1 mRNA levels, the resistance factor (RF), and the efficiency of efflux of pirarubicin (THP) mediated by P-glycoprotein (P-gp) in multidrug-resistant (MDR) K562 sublines. pirarubicin 160-163 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 12489924-1 2002 In this work, we sought to investigate the relation existing between MDR1 mRNA levels, the resistance factor (RF), and the efficiency of efflux of pirarubicin (THP) mediated by P-glycoprotein (P-gp) in multidrug-resistant (MDR) K562 sublines. pirarubicin 160-163 ATP binding cassette subfamily B member 1 Homo sapiens 177-191 12489924-1 2002 In this work, we sought to investigate the relation existing between MDR1 mRNA levels, the resistance factor (RF), and the efficiency of efflux of pirarubicin (THP) mediated by P-glycoprotein (P-gp) in multidrug-resistant (MDR) K562 sublines. pirarubicin 160-163 ATP binding cassette subfamily B member 1 Homo sapiens 193-197 12489924-4 2002 We used spectrofluorometric methods to determine the kinetics of the uptake and P-gp-mediated efflux of THP in the different selected MDR K562 sublines. pirarubicin 104-107 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 12489924-10 2002 The P-gp-mediated efflux of THP and an accumulation of THP in acidic organelles confer an advantage for MDR cells in surviving prolonged exposure to cytotoxic agents and giving rise to high degrees of resistance. pirarubicin 28-31 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 7904185-0 1994 Non-competitive inhibition of P-glycoprotein-associated efflux of THP-adriamycin by verapamil in living K562 leukemia cells. pirarubicin 66-80 ATP binding cassette subfamily B member 1 Homo sapiens 30-44 9744556-7 1998 At pH 7.2, 50% of the P-glycoprotein-mediated efflux of daunorubicin and idarubicin was inhibited by about 40 +/- 10 microM vinblastine and that of pirarubicin by 10 +/- 2 microM vinblastine. pirarubicin 148-159 ATP binding cassette subfamily B member 1 Homo sapiens 22-36 9744556-11 1998 A detailed kinetics analysis of the P-glycoprotein-mediated efflux of pirarubicin in the presence of vinblastine indicates a non competitive inhibition with K(I) = 12 +/- 2 microM. pirarubicin 70-81 ATP binding cassette subfamily B member 1 Homo sapiens 36-50 9615748-0 1998 Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues. pirarubicin 0-11 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 9615748-10 1998 Pgp was expressed in 23.5% (12/51) specimens and the efficacy of anthracyclines was reduced in Pgp-positive breast cancer tissues, although this reduction was low in THP with a statistically significant difference when comparing with DXR and EPIR. pirarubicin 166-169 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 9443942-8 1998 Two anthracyclines, the doxorubicin derivative pirarubicin and 2"-bromo-4"-epi-DNR seemed to have a slightly higher Ka value for Pgp than for MRP. pirarubicin 47-58 ATP binding cassette subfamily B member 1 Homo sapiens 129-132 11791127-0 2001 Resistant mechanisms of anthracyclines--pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues. pirarubicin 40-51 ATP binding cassette subfamily B member 1 Homo sapiens 83-97 10418960-6 1999 For this purpose, cells were irradiated in the presence of VP* and various concentrations of either verapamil or of one of the anthracyclines and then the P-gp functionality was checked by its ability to pump pirarubicin. pirarubicin 209-220 ATP binding cassette subfamily B member 1 Homo sapiens 155-159 26410305-3 2015 Mechanistically, DAB2IP could inhibit the phosphorylation and transactivation of STAT3, and then subsequently suppress the expression of Twist1 and its target gene P-glycoprotein, both of which were crucial for the pirarubicin chemoresistance and tumor re-growth of bladder cancer cells. pirarubicin 215-226 ATP binding cassette subfamily B member 1 Homo sapiens 164-178 34476509-0 2021 Gallic acid enhances pirarubicin-induced anticancer in living K562 and K562/Dox leukemia cancer cells through cellular energetic state impairment and P-glycoprotein inhibition. pirarubicin 21-32 ATP binding cassette subfamily B member 1 Homo sapiens 150-164 30924055-6 2019 The kinetic of P-glycoprotein-mediated efflux pirarubicin was used to monitor P-glycoprotein function in multidrug resistant (MDR) cancer cells. pirarubicin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 15-29 30924055-6 2019 The kinetic of P-glycoprotein-mediated efflux pirarubicin was used to monitor P-glycoprotein function in multidrug resistant (MDR) cancer cells. pirarubicin 46-57 ATP binding cassette subfamily B member 1 Homo sapiens 78-92 27744704-6 2016 PAMV6/THP was able to reverse MDR more than free THP in MCF-7/ADR cells, likely reflecting the remarkably higher intracellular THP concentration in micelle-treated cells and PAMV6-mediated inhibition of P-gp activity. pirarubicin 6-9 ATP binding cassette subfamily B member 1 Homo sapiens 203-207 20104851-5 2010 Compound 9 shows the most promising properties as it was able to nearly completely reverse Pgp-dependent pirarubicin extrusion at nanomolar doses and increased the cytotoxicity of doxorubicin with a reversal fold (RF) of 19.1 at 3 microM dose. pirarubicin 105-116 ATP binding cassette subfamily B member 1 Homo sapiens 91-94 25591827-7 2015 Similarly, P-gp of pirarubicin was unaffected by Abeta42. pirarubicin 19-30 ATP binding cassette subfamily B member 1 Homo sapiens 11-15